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Abstract
Questions concerning the diagnosis and treatment of ulcer­
ative colitis (UC) in Ukraine are described, in recent years, 
there has been considerable progress in conservative thera­
py and new drugs have been developed that provide persis­
tent remission of the inflammatory process after long-term 
application in many cases. The results of our own investiga­
tion on the efficiency of rebamipide in the complex treat­
ment of UC patients are presented. Optimization of treat­
ment with substitution of mesalazine in tablet or granule 
form, especially with an additional rebamipide prescription 
and a once-daily administration of budesonide, leads to an 
increased effectiveness of treatment and improvement of 
quality of life in UC patients. In the future, development 
of new approaches in the pharmacotherapy of UC will use 
medications as a basic therapy with the purpose of achiev­
ing high-quality and effective 'convalescence of mucous 
membrane', including cytoprotectors, bilious acids, endog­
enous substances, stabilization of membranes, antihyp- 
oxantsand correction of microbiocenosis disorders.
Copyright © 2009 S. Karger AG, Basel
introduction
Ulcerative colitis (UC) is one of the most difficult and 
unsolved problems of modern medicine, and because of 
its severity, frequency of complications and lethality, it 
occupies one of the first places on the list of gastrointes­
tinal tract diseases. There is an increasing tendency of UC 
frequency and an ‘epidemic’ is forecasted for Eastern Eu­
rope, including Ukraine, In Europe, UC morbidity has 
increased practically twofold in the last 10 years and com­
prises 8-12 cases per 100,000 inhabitants annually. The 
pasMende of UC has also had a tendency to grow and 
comprises 40-117 patients per 100,000 inhabitants [1].
The epidemiological indexes of this disease in Ukraine 
differ because of the predominance of its serious and 
complicated forms. The variety of clinical forms compli­
cates diagnosis and estimation of activity of the process 
in the aggravation phase. Thus, the risk of complications 
rises due to inadequate treatment, the disability of pa­
tients being able to work, and the increase of lethality.
Pathogenesis
As the questions of etiology and pathogenesis of UC 
have not been studied too well, the development of early 
diagnosis principles of the disease is difficult. Recent de-
KARGEK
Fax +41 61 306 12 34 
E-Mail karger@karger.ch 
www.karger.com
© 2009 S. Karger AG, Basel 
0257-2753/09/0274-0550526.00/0
Accessible online at: 
www. ka rger.com/dd і
I.N. Skrypnyk
Therapy D epartm ent, Postgraduate Education Faculty 
Ukrainian Medical Stomatological Academy 
23 Shevchenko Street, UA-36024 Poltava (Ukraine)
Tel. +380 5322 24395, Fax +380 5322 693 213, E-Mail scrin69@yandex.ru
DDI133.indd 550 27.08.2009 10:23:57
cades are characterized by considerable expansion and 
deepening of concepts about the pathogenesis of intestine 
inflammatory diseases on the basis of the genetic and ep­
idemiological research that has been conducted.
UC is a polyetiological disease in which the genetic 
predisposition plays a leading role, due to immunological 
mechanisms under the influence of stress factors, eating 
disorders and allergy. In the Donetsk region of Ukraine, 
a genetic predisposition of UC was found in 19.8% of cas­
es, different types of allergy in 21.5%, and protracted 
chemical influences, related to the features of profession, 
in 6% cases. Immunological and eating disorders were 
observed in all patients [2].
60% of UC patients hav^ e a mild form of the disease, 
and the typical intermittent course of disease takes place 
in 30% of the patients. The existence of different types of 
UC is conditioned by genetic features (polymorphism of 
NOD2/CARD15 gene), the influence on the organism of 
external environmental factors, and patients having 
harmful habits [3]. It was recently determined that ap­
pendectomy as well as smoking reduce the risk of UC de­
velopment associated with the severe course of the dis­
ease [4, 5]. Glycoprotein P plays a very important role in 
protecting against coli bacteria and toxins, and breaking 
the barrier’s function for genotype 3435TT possessors 
can stipulate their predisposition to UC [6]. The impor­
tant role of breaking the resistance of the intestines mu­
cous membrane-protective barrier in UC pathogenesis 
has been confirmed by the discovery of ASCA antibodies 
in the blood serum of these patients (antibodies to Sac- ! 
charomyccs cercvisiae). However, they are not a patho­
gnomonic diagnostic UC index, because they are often 
found in UC patients’ relatives who have no signs of this 
disease manifestation [3].
Diagnostics
The clinical picture consists of intestinal symptoms 
which are characteristic for all patients and intestinal in­
dications are practically found in 50% of the patients. 
With the standardization of the clinical picture, the in­
dexes of the clinical activity of Rachmilewitz and Mayo 
disease are presently used. However, these indexes are 
used for scientific research but not in doctors’ surgeries 
in Ukraine. It is important to evaluate not only the prev­
alence of the inflammatory process in the colon and dis­
ease activity, but also the degree of gravity. Except for 
immune changes of patients with UC, a dysbalance of 
the cytokine regulation was revealed with a predomi­
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nance of proinflammatory cytokines such as tumor 
necrotic factor-а  (TNF-a), interleukins (IL)-l, -6, -8, 
-12 and a decrease of anti-inflammatory IL-4, -10, and 
-11 [7].
It is necessary to provide endoscopic research with a 
biopsy in dynamics. Capsule videoendoscopy is the most 
informative and objective method of investigation in this 
respect. Histological research is the standard in diagnosis 
of UC. For the patients with UC in the stage of remission, 
endoscopy of the colon must be provided not less than 
once during 6-8 months. Irrigography is an additional 
diagnostic method and allows to evaluate the prevalence 
of inflammation in colon in case it is not possible to per­
form colonoscopy.
High-quality determination of stool protein in feces as 
the most exact and sensible indicator of this disease activ­
ity is reasonable for the diagnosis of inflammatory dis­
eases of the intestine and irritated intestine syndrome. 
Stool protein is produced by neutrocytes, and if patients 
suffer from intestinal inflammatory diseases, an in­
creased amount secretes through the bowel wall as a re­
sult ofleukocyte migration [8|. In UC feces stool protein, 
sensitivity is 94.1% and specificity is 80%. A marker is a 
more exact indicator of the inflammatory process than 
red corpuscles (p < 0.01) and C-reactive protein (p < 
0.001). The level of feces stool protein correlates well with 
UC activity (p < 0.001) [9].
Treatment
The traditional and generally recognized tasks of 
treatment are to reduce disease activity, reduce expressed 
clinical symptoms, improve patients’ quality of life, and 
prevent relapses. Before beginning treatment it is impor­
tant to estimate therapy possibilities taking the following 
into account: localization and gravity of the process, 
presence of complications, response to the previously ap­
plied therapy is important to create an individual chart 
of the patient’s treatment, and estimate the prospect of 
applied therapy.
Basic medicinal therapy of UC is conducted depend­
ing on the gravity of colitis and includes derivates of 
mesalazine, topical steroids (first-line), cytostatics and 
biological preparations (second-line). Basic UC therapy 
must be provided independent of the gravity of colitis ac­
cording to ECCO recommendations. Mesalazine is pre­
scribed in case of minimal activity at a dose of 3-4 g/dav 
orally and is rectally independent of the process [10]. 
Mesalazine (Eudragit L) granules provide the prolonged
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liberation of active matter and have maximal contact 
with the mucous membrane of distal parts of the intes­
tine [11].
Rectal application of steroids, mainly topical steroids, 
is indicated with the purpose of minimizing side effects 
[12]. We prescribe mesalazine 4-8 g/day and budesonide 
9 mg/day in cases of moderate activity. A daily dose of 
9 mg budesonide possesses greater efficiency if taken 
once daily over an 8-week period than if taken 3 mg three 
times a day. The efficiency with single dose of budesonide 
is related to a considerably higher concentration of prep­
aration in blood serum and also higher absolute bioavail­
ability [13]. We prescribe high doses of mesalazine, 
>8 g/day, in patients with severe forms of UC. The dose 
of budesonide is increased up to 18 mg/day, and we then 
combine it with steroids. Because of the ineffectiveness of 
mesalazine and budesonide application, high second-line 
doses are prescribed, e.g. immunosuppressors or biologi­
cal therapy preparations. Difficulties of therapy are that 
25-30% of patients are resistant to basic therapy with 
standard doses, and that the side effects due to system­
ic glucocorticoids and immunosuppressants are fore­
casted.
Azathioprine is suitable for chronic slack steroid-resis­
tant and steroid-dependent active forms oftJC treatment, 
supporting disease remission and cannot be used in acute 
situations. To achieve a maximal effect, 4-6 months are 
required. Prescribing azathioprine in a complex with ste­
roids allows to reduce the preparation dose. However, 
prolonged azathioprine use leads to the development of 
colon neoplasia in UC patients [14].
The observation in patients who had taken azathio­
prine for 7 years testifies the necessity of conducting col­
ectomy in 88% of the cases. Patients who did not take 
azathioprine had better results [15]. Short-term cyclo­
sporine treatment is effective in steroid-dependent UC 
and is an alternative treatment for glucocorticoid thera­
py in patients with a severe attack. In glucocorticoid and 
cytostatic refractory forms of UC, inhibitors of TNF-a 
are used such as adalimumab and certolizumab -  the 
clinical effects of application of which are similar to that 
of in-fliximab. According to the results of two placebo- 
controlled reports [16, 17], infliximab application leads 
to a clinical improvement and remission in patients with 
severe intensity and middle gravity intensity of UC, 
which did not react to standard therapy. However, cur­
rently the US FDA has only approved natalizumab. The 
future perspective is application of recombinant human 
IL-10 [2].
The ultimate goal of treatment nowadays is removing 
or improving patients’ complaints and symptoms, pro­
phylaxis or reducing complications and in the future 
convalescence’ of mucous membrane and development 
of etiotropic therapy. A promising trend in UC treatment 
is the use of cytoprotectors, which will lead to an in­
creased resistance of the bowels’ mucosal epithelial cells. 
Rebamipide is a novel agent that stimulates mucosal epi­
thelial cell regeneration by increasing the expression of 
epithelial growth factor. We examined 25 patients with 
an average severe course of UC (the index of clinical ac­
tivity 6-12; endoscopic index 4 according to Rachmile- 
witz, 1989) who were divided into three groups depend­
ing on curative complexes: group I (n = 9): mesalazine 
(tablets) 3 g/day and budesonide 9 mg/day taken 3 times; 
group II (n = 8): mesalazine (granules) 3 g/day and 
budesonide 9 mg/day taken once; group III (n = 8): me­
salazine (granules) 3 g/day and budesonide 9 mg/day tak­
en once + rebamipide 300 mg/day.
Clinical, endoscopic assessments were made at base­
line and the end of the study and symptoms were re­
corded On a daily basis. The primary endpoint was in­
troduction of clinical remission and clinical improve­
ment was also measured using the UC disease activity 
index. The exchange of fuco- and sialoproteins was es­
timated according to their concentration in blood and 
the level of their excretion with urine, taking into ac­
count the state of the patients. Studying the state of the 
protective mucous barrier in intestinal inflammatory 
diseases is particularly important, as well as establish- 
I ing any damage as a result of inflammation and ulcer­
ation.
The largest number of patients in the clinical remis­
sion phase after 8 weeks of therapy was recorded: in group 
111, 6 patients (75%), in group II, 5 patients (62.5%), and 
in group I, 5 patients (55.6%). The duration of clinical re­
mission was: 24.7 ± 1.4 days in group I, 27.5 ± 1.7 days 
in group II, and 30.7 ± 1.8 days in group III (p > 0.05). 
Endoscopic remission was detected in 3 (33.3%) patients 
of group I, in 4 (50%) patients of group II, and in 5 (62.5%) 
patients of group III.
An increased concentration of iV-acetylneuraminic 
acid was detected in the patients of all groups as well as a 
1.8 times decrease of the blood fucose level in connection 
with albumin (p < 0.05). The prescription of curative 
complexes leads to a reduction of N-acetyl neuraminic 
acid of 1.4 times and in fucose to an increase of 1.5 times 
in blood, which is significantly expressed in group III 
(p <  0.05). The same changes were detected in the exam­
ination of excretion of fucose in urine.
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During a previously conducted multicenter research 
in patients with medially severe and severe UC, it was 
found that rebamipide s efficiency in enemas was similar 
to the effect of 5-aminosalicylic acid on the background 
of basic therapy in the disease activity index, endoscopic 
index score, endoscopic grading scale, and biopsy score 
[18). Analogous results were obtained by the research of 
Ogata et al. [19] in which rehamipide’s efficiency in ene­
mas was observed in UC through strengthening the ex­
pressiveness of intercellular protein of claudin-1 in the 
intestine’s epithelial cells. Rebamipide has a broad spec­
trum of pharmacological actions that include suppres­
sion of neutrophil functions and stimulation of mucosal 
epithelial cell regeneration. Thus, rebamipide renders a 
protective effect on the mucous membrane of intestine by 
strengthening the expressiveness of epithelial factor of 
growth, reducing peroxide oxidation in the mucous 
membrane of intestine, stimulating regeneration of the 
mucous membrane of intestine, and suppressing the 
function of neutrophils [20, 21].
When comprising treatment complexes for UC pa­
tients, it is necessary to take into account the presence of 
viral and bacterial superinfections that can imitate an in­
tensification of the disease. Probiotic preparations of Lac­
tobacillus GG are effective and safe for UC patients in a 
composition of antirecurrent complexes in combination 
with mesalazine. Lactobacillus GG treatment is more ef­
fective than standard therapy on the basis of mesalazine 
with regard to duration; it is free from intensification 
(p <  0.05) and can be used as a component of antirecur­
rent therapy [22].
Determining the important role of mucous barrier re­
sistance of intestine in UC, pathogenesis serves as a basis 
for optimization of medical complexes with the use of 
antibacterial preparations, probiotics, phosphatidylcho­
line and preparations of bilious acids. In inflammatory 
diseases of the bowel, the protective ability of mucous 
membrane collapses with inflammation and ulceration 
that is related to the cooperation between the immune 
system, genetic predisposition and environment.
In experimental colitis using rat models, an increase 
of bacterial translocation is registered which diminishes 
when melatonin is administered. In the group of ani­
mals with experimental colitis that were given melato­
nin, there is a marked decrease of the TNF-a concentra­
tion, caspase-3 activity and endotoxin level in blood se­
rum [23]. Essential phospholipids are prescribed with 
the purpose of strengthening the resistance of epithelial 
cell membranes in the intestine, improving their plas­
ticity and also such effects as antioxidative, disaggrega-
tional effect, immunomodulation on a cellular level, re­
storing damaged membrane structures of the cell, and 
increasing prostaglandin synthesis [24-26]. Thus, si­
multaneously essential phospholipids render a hepato- 
protective effect that is extremely important during the 
protracted therapy with aminosalicylates and glucocor­
ticoids.
An important direction in the realization of the con­
cept o f‘convalescence of mucous membrane’ is prescrib­
ing antihypoxants with the purpose of removing tissue 
hypoxia and improving blood circulation into the mu­
cous membrane of the intestine. The preparation of 
choice is a deproteinized hemoderivate which provides 
an increase of the energetic potential of cells (an increase 
of 5 times the cell consumption of glucose), reduces in­
flammatory-cellular infiltration, anabolism action, im­
proves blood supply and removes tissue hypoxia.
The influence of UC on quality of life, related to the 
health of patients, was estimated for 26 patients in an 
Italian university clinic study [27]. Three questionnaires 
given to the patients at the ambulatory visit were used, 
namely SF-36 (general well-confirmed method of mea- 
suringof quality of life, related to the health), SCL-90 (for 
the evaluation of the psychological state of patients) and 
the Holmes-Rahe scale (for evaluation of vital stress situ­
ations). The decrease of quality of life, related to health, 
and general severity of psychological symptoms is set in 
UC patients and irritable intestine syndrome. Thus, the 
gravity of the last vital stress situation is considered as 
ibeing more difficult in irritable intestine syndrome pa­
tients in comparison with UC. The basic task of treat­
ment is not only induction of remission and temporal 
removal of symptoms, but also maintenance of protract­
ed remission, maintenance of the patient’s quality of life 
and prophylaxis of new malignant formations of the co­
lon [28].
Conclusion
Thus, optimization of the curative complexes with the 
substitution of mesalazine in tablet or granule form, es­
pecially with an additional rebamipide prescription, as a 
once-daily dose of budesonide will lead to an increase of 
treatment effectiveness and improvement of overall qual­
ity of life in UC patients. In the future, development of 
new approaches in the pharmacotherapy of UC will use 
medications on the background of basic therapy with the 
purpose of achieving high-quality and effective ‘conva­
lescence of mucous membrane’, including cytoprotectors
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(rebamipide), bilious adds (ursodeoxycholic acid), en- Disclosure Statement 
dogenous substances (melatonin), stabilization of mem­
branes (phosphatidylcholine), antihypoxants (deprotein- 
ized hemoderivate) and correction of microbiocenosis 
disorders.
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